Company intelligence / Profile preview

Equinox Sciences

Newport Beach, California, United States

Ownership: Private
Development stage: Other

Overview

Vorolanib, a small-molecule tyrosine kinase inhibitor targeting PDGFR and VEGFR, has demonstrated positive Phase 1 clinical results for wet AMD (EYP-1901, via EyePoint's delivery system). Approved in China for renal cell carcinoma; multiple ophthalmic trials ongoing/planned.

Therapeutic areas: OncologyOphthalmology
Modalities: Small molecule
Industry: Biotech

Partnerships

EyePoint Pharmaceuticals (exclusive global ophthalmic license, outside China)Betta Pharmaceuticals (China regional rights)

Beyond the preview

Go deeper on Equinox Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equinox Sciences.

Explore the full profile